Tenecteplase
Administration
- Type: Thrombolytic
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names:
Adult Dosing
Acute myocardial infarction
- <60kg: 30mg IV bolus over 5s
- 60-69kg: 35 mg IV bolus over 5s
- 70-79 kg: 40 mg IV bolus over 5s
- 80-89kg: 45 mg IV bolus over 5s
- >90 kg: 50 mg IV bolus over 5s
Pediatric Dosing
Safety/efficacy not established
Special Populations
Pregnancy Rating
- Pregnancy category C (fetal risk cannot be ruled out)
Lactation risk
- Infant risk cannot be ruled out
Renal Dosing
- Adult: not established
Hepatic Dosing
- Adult: not established
Contraindications
- Allergy to class/drug
- Active internal bleeding
- Known bleeding diathesis
- Recent (<2m) intracranial or intraspinal surgery or trauma
- Intracranial neoplasm, AVM, or aneurysm
- History of CVA
- Severe, uncontrollable hypertension
Adverse Reactions
Serious
- Upon coronary reperfusion: Dysrhythmia, cholesterol embolus (rare)
- Major hemorrhage, GI bleed, intracranial hemorrhage, renal artery hemorrhage
- CVA
- Thromboembolism
- Anaphylaxis, hypersensitivity reaction
Common
- Minor hemorrhage: hematoma, GI bleed, renal artery hemorrhage
Pharmacology
- Half-life: 90-130m
- Metabolism: Hepatic
- Excretion:
Mechanism of Action
- Binds fibrin, converts plasminogen to plasmin
Comments
References
- Fatovich D, Dobb G, Clugston R. A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). Resuscitation. 2004;61(3):309-313.
- Bozeman W, Kleiner D, Ferguson K. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation. 2006;69(3):399-406.
- Böttiger B, Arntz H, Chamberlain D, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008;359(25):2651-2662.
- Micromedex
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.